Hepatic resection or transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus

Abstract

The role of hepatic resection in hepatocellular carcinoma (HCC) with accompanying portal vein tumor thrombus (PVTT) remains controversial. This study aimed to evaluate the surgical outcomes of hepatic resection compared with those of transarterial chemoembolization (TACE) in HCC patients. A retrospective study was conducted using the medical records of 230 HCC patients with portal vein invasion who underwent hepatic resection (96 patients) or TACE (134 patients). The baseline characteristics, tumor characteristics, clinicopathological parameters, and overall survival rates were compared between the 2 groups. The baseline and tumor characteristics were comparable between the hepatic resection and TACE groups. The overall complication rate was 35.4% in the hepatic resection group, which was significantly lower than that in the TACE group (73.0%, P <0.001). However, the serious complication rate (grade ≥3) in the hepatic resection group was 13.5%, which was significantly higher than that in the TACE group (P = 0.003). The cumulative overall survival rates at 1, 3, and 5 years in the hepatic resection group were 86.5%, 60.4%, and 33.3%, respectively. These rates were much higher than those in the TACE group (1-year: 77.6%; 3-year: 47.8%; and 5-year: 20.9%; P = 0.021). The long-term survival was notably better in the patients with types I and II PVTT than in the patients with types III and IV PVTT (P <0.05). The univariate and multivariate analyses indicated that types III and IV PVTT and TACE may have contributed to the poor overall survival following surgery. In HCC patients with PVTT and compensated liver function, hepatic resection is a safe and effective surgical protocol, particularly for patients with type I or II PVTT.

Figure 1

A comparison of the overall survival curves for HCC patients with PVTT who were treated with hepatic resection or TACE. The 1-, 3-, and 5-year overall survival rates in the hepatic resection group were 86.5%, 60.4%, and 33.3%, respectively. These rates were significantly higher than those in the TACE group (1-year: 77.6%; 3-year: 47.8%; and 5-year: 20.9%; P = 0.021).

Figure 2

A comparison of the overall survival curves for HCC patients with different types of PVTT. Types I and II PVTT were associated with comparable long-term survival (P > 0.05). Additionally, types III and IV PVTT were associated with comparable long-term survival. However, the long-term survival in patients with type II PVTT was much better than that in patients with type III PVTT (P < 0.05).